

## Supplementary material

---

Iwańczyk S, Smukowska-Gorynia A, Woźniak P, et al. Increased endocan expression as a biomarker of endothelial dysfunction in patients with metabolic syndrome. *Pol Arch Intern Med.* 2022; 132: 16292. doi:10.20452/pamw.16292

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

**Table S1.** Univariable and multivariable logistic regression model for MS.

Variable	Univariable analysis [OR (95% CI)]	P-value <sup>a</sup>	Multivariable analysis [OR (95% CI)]	P-value <sup>a</sup>
CAD	5.1 (1.4, 18.4)	0.003	5.4 (1.7, 17.4)	0.004
Endocan, ng/L	1.001 (1.0002, 1.002)	0.002	1.001 (1.0002, 1.003)	0.002
WBC, 10 <sup>9</sup> /L	1.3 (1.04, 1.6)	0.02	0.9 (0.4, 2.0)	0.7
NEUT, 10 <sup>9</sup> /L	1.4 (1.04, 1.9)	0.02	1.4 (0.5, 3.6)	0.5

<sup>a</sup> p <0.05 for all comparisons

Abbreviations: CI, confidence interval; LDL, low-density lipoprotein; MS, metabolic syndrome; WBC, white blood cells;

Variables with P-value<0.1 in the univariable analysis were introduced into the multivariable logistic regression model

**Figure S1.** Plasma levels of Endocan in MS group compared to non-MS group.

